Tag: NASDAQ:ALLK

January 29, 2019

Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

Allakos (NASDAQ:ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive...
August 7, 2018

4 Biotechnology IPOs in July

The Investing News Network provides a look back at four biotechnology stocks that launched on the NASDAQ during the month...